Literature DB >> 20590628

Histamine inhibits adhesion molecule expression in human monocytes, induced by advanced glycation end products, during the mixed lymphocyte reaction.

J Zhang1, H K Takahashi, K Liu, H Wake, R Liu, H Sadamori, H Matsuda, T Yagi, T Yoshino, S Mori, M Nishibori.   

Abstract

BACKGROUND AND
PURPOSE: Post-transplant diabetes mellitus is a frequent complication among transplant recipients. Ligation of advanced glycation end products (AGEs) with their receptor on monocytes/macrophages plays important roles in the genesis of diabetic complications. The enhancement of adhesion molecule expression on monocytes/macrophages activates T-cells, reducing allograft survival. Out of four distinct AGE subtypes (AGE-2, AGE-3, AGE-4 and AGE-5), only AGE-2 and AGE-3 induced expression of intercellular adhesion molecules (ICAMs), output of cytokines and proliferation of lymphocytes, during the mixed lymphocyte reaction (MLR). Here we have assessed the role of histamine in the actions of AGEs during the MLR. EXPERIMENTAL APPROACH: Human peripheral blood cells were used in these experiments. Flow cytometry was used to examine the expression of the ICAM-1, B7.1, B7.2 and CD40. Production of the cytokine interferon-gamma, and levels of cAMP were determined by elisa. Lymphocyte proliferation was determined by [(3)H]-thymidine uptake. KEY
RESULTS: Histamine concentration dependently inhibited the action of AGE-2 and AGE-3. The actions of histamine were antagonized by an H(2)-receptor antagonist, famotidine, and mimicked by H(2)/H(4)-receptor agonists, dimaprit and 4-methylhistamine. The effects of histamine were reversed by a protein kinase A (PKA) inhibitor, H89, and mimicked by dibutyryl cAMP and an adenylate cyclase activator, forskolin. CONCLUSIONS AND IMPLICATIONS: Histamine down-regulated AGE-2- and AGE-3-induced expression of adhesion molecules, cytokine production and lymphocyte proliferation via histamine H(2) receptors and the cAMP/PKA pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590628      PMCID: PMC2938809          DOI: 10.1111/j.1476-5381.2010.00800.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

Review 1.  Genomics meets histamine receptors: new subtypes, new receptors.

Authors:  L B Hough
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

Review 2.  Diabetes and advanced glycation endproducts.

Authors:  H Vlassara; M R Palace
Journal:  J Intern Med       Date:  2002-02       Impact factor: 8.989

Review 3.  Glycaemic control and graft loss following renal transplantation.

Authors:  M C Thomas; T H Mathew; G R Russ
Journal:  Nephrol Dial Transplant       Date:  2001-10       Impact factor: 5.992

4.  Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.

Authors:  Sho-ichi Yamagishi; Shinjiro Amano; Yosuke Inagaki; Tamami Okamoto; Kohachiro Koga; Nobuyuki Sasaki; Hiroshi Yamamoto; Masayoshi Takeuchi; Zenji Makita
Journal:  Biochem Biophys Res Commun       Date:  2002-01-25       Impact factor: 3.575

5.  Increased expression of inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients with acute rejection: decline with resolution of rejection.

Authors:  M Rizzo; K S SivaSai; M A Smith; E P Trulock; J P Lynch; G A Patterson; T Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2000-09       Impact factor: 10.247

6.  Enhanced acute-phase response and oxidative stress in older adults with type II diabetes.

Authors:  F Arnalich; A Hernanz; D López-Maderuelo; J M Peña; J Camacho; R Madero; J J Vázquez; C Montiel
Journal:  Horm Metab Res       Date:  2000-10       Impact factor: 2.936

7.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.

Authors:  Nozomu Tanji; Glen S Markowitz; Caifeng Fu; Thomas Kislinger; Akihiko Taguchi; Monika Pischetsrieder; David Stern; Ann Marie Schmidt; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2000-09       Impact factor: 10.121

8.  Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

Authors:  Tamami Okamoto; Sho-ichi Yamagishi; Yosuke Inagaki; Shinjiro Amano; Kohachiro Koga; Riichiro Abe; Masayoshi Takeuchi; Shigeaki Ohno; Akihiko Yoshimura; Zenji Makita
Journal:  FASEB J       Date:  2002-10-04       Impact factor: 5.191

9.  Effect of histamine on intercellular adhesion molecule-1 expression and production of interferon-gamma and interleukin-12 in mixed lymphocyte reaction stimulated with interleukin-18.

Authors:  Hideyuki Itoh; Hideo K Takahashi; Hiromi Iwagaki; Tadashi Yoshino; Yoshinori Morimoto; Shinnya Saito; Takahito Yagi; Tadaatsu Akagi; Masahiro Nishibori; Noriaki Tanaka
Journal:  Transplantation       Date:  2002-09-27       Impact factor: 4.939

10.  Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors.

Authors:  N B Sumrani; V Delaney; Z K Ding; R Davis; P Daskalakis; E A Friedman; K M Butt; J H Hong
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

View more
  3 in total

Review 1.  Histamine in the Crosstalk Between Innate Immune Cells and Neurons: Relevance for Brain Homeostasis and Disease.

Authors:  Liliana Bernardino
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Aberrant glycosylation of plasma proteins in severe preeclampsia promotes monocyte adhesion.

Authors:  Shannon K Flood-Nichols; Avedis A Kazanjian; Deborah Tinnemore; Philip R Gafken; Yuko Ogata; Peter G Napolitano; Jonathan D Stallings; Danielle L Ippolito
Journal:  Reprod Sci       Date:  2013-06-11       Impact factor: 3.060

3.  Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice.

Authors:  Ava Vila-Leahey; Sharon A Oldford; Paola A Marignani; Jun Wang; Ian D Haidl; Jean S Marshall
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.